← Larimar Therapeutics, Inc. (LRMR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Larimar Therapeutics, Inc. (LRMR)
Pharmaceutical Preparations · market cap $393M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
2
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Larimar Therapeutics (LRMR) is a small-cap pharmaceutical company with 65 employees and a ~$354M market cap, built entirely around a single asset: CTI-1601, currently in Phase 2 for Friedreich Ataxia (FA). The company carries $177.9M in cash against no revenue, with an estimated 12-month runway and a potential PDUFA date as early as February 2027, making the next 7–8 months binary for the story.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2027-01-15 (est.)Phase 2 · CTI-1601imp 7/10
- 2027-02-24 (est.)PDUFA · CTI-1601imp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CTI-1601 | Phase 2 | Friedreich Ataxia |
| Nomlabofusp | Phase 3 | Friedreich Ataxia |
Price & technical context
3-month
-6.1%
6-month
-34.6%
12-month
-5.3%
52-wk range
$2.81–$5.95
vs 50-day MA
-21.5%
vs 200-day MA
-22.2%
Realized vol
90.6%
Max drawdown
-81.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LRMR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.